Evaluation of Lung Adverse Events Associated With Lenvatinib: A Post-marketing Surveillance Study
The present study highlights post-marketing AEs associated with lenvatinib, with a particular focus on lung AEs. Tracheal fistula and tracheal haemorrhage were identified as AEs with potentially serious outcomes following lenvatinib administration. Monitoring patients for early signs of these AEs is important not only at treatment initiation, but also throughout the entire course of therapy.
Authors
- Yoshiaki Kaneko (ORCID: https://orcid.org/0000-0001-9611-2303)
- Yuko Kanbayashi (ORCID: https://orcid.org/0000-0002-0095-2293)
- Tadashi Shimizu (ORCID: https://orcid.org/0000-0002-5563-6730)
- HARUKA WAKABAYASHI
- Mayako Uchida (ORCID: https://orcid.org/0000-0003-0507-7309)
- Momoko Kobayashi (ORCID: https://orcid.org/0000-0003-2160-2011)
Institutions
- Doshisha Women's College of Liberal Arts (JP)
- Hyogo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2024-12-31
- DOI
- https://doi.org/10.21873/invivo.13834
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Taiho Pharmaceutical